Tabula Rasa HealthCare’s DoseMe Executes First-ever integration of its Precision Dosing Software with market-leading Electronic Medical Record provider

- April 5th, 2019

Tabula Rasa HealthCare (NASDAQ:TRHC) has announced that its newly-acquired software company, DoseMe, has completed the first fully-integrated precision dosing software solution. As quoted in the press release: DoseMeRx,™, integrated with market leading hospital electronic health record providers, allows hospital users to swiftly, easily and securely launch independent applications from the hospital’s own system using de-identified … Continued

Tabula Rasa HealthCare (NASDAQ:TRHC) has announced that its newly-acquired software company, DoseMe, has completed the first fully-integrated precision dosing software solution.

As quoted in the press release:

DoseMeRx,™, integrated with market leading hospital electronic health record providers, allows hospital users to swiftly, easily and securely launch independent applications from the hospital’s own system using de-identified information.  Utilizing industry leading software language, commonly referred to as SMART-on-FHIR, hospitals access TRHC’s clinical decision support software to individualize the dose of medications to help healthcare professionals easily optimize therapy for each patient, resulting in improvements to mortality, risk and patient outcomes, as well as saving hours of pharmacist time performing manual calculations.

“We are pleased with the traction our recently-acquired DoseMeRx is garnering in the United States in helping patients with precision, parenteral pharmacotherapy,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “We believe this trend will continue as hospitals and healthcare systems become more patient-centered and realize the clinical and economic benefits of incorporating DoseMeRx into their narrow-therapeutic index drug protocols.”

TRHC’s focus is on providing solutions for individualizing the dose of medications to help healthcare professionals easily optimize therapy for each patient, resulting in improvements to mortality, risk and patient outcomes. TRHC’s technology now supports dose optimization for tens of thousands of patients, for more than 1,250 clinicians and across more than 130 locations world-wide.

“Being the world’s leading precision dosing software comes with the responsibility of advancing the access and utility of such solutions.  We have known for some time that we were ahead of the market in promoting integrated clinical decision support software (CDSS) within the acute hospital setting; so, to go live with such a prestigious group, one that is known as an innovator and a leader in clinical care makes it so worthwhile.  Our organization is built around three fundamental elements – great science, clinical importance and brilliant usability.  This integration brings these elements together, resulting in improved workflows, cost savings and better patient outcomes, all while empowering the pharmacist to be her or his best,” said Charles Cornish, Chief Executive Officer of DoseMe.

Click here to read the full press release.

Read our new 2019 medical device report today

 

 

Including: 3+ stocks to watch as well as valuable market data   Get My Free Report Click here to download for free

Leave a Reply

Your email address will not be published. Required fields are marked *